Every 8-K that Neumora Therapeutics, Inc. (NMRA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow NMRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NMRA filings page.
Neumora Therapeutics, Inc. reported financial results for the quarter ended June 30, 2026 and outlined key pipeline and leadership developments. The company had $116.8 million in cash and cash equivalents and expects this to fund its operating plan into the third quarter of 2027. Research and development expenses were $29.3 million, down from $38.7 million a year earlier, and general and administrative expenses were $12.9 million, down from $15.3 million. Net loss for the quarter was $43.1 million compared with $52.7 million in the prior-year period.
Neumora reported favorable pre-clinical data for NMRA-215 and plans to submit an IND in the fourth quarter of 2026 and start a Phase 1 study by year-end 2026. It plans Phase 1 data for NMRA-898 in the second half of 2026 and MAD expansion data plus Phase 2 initiation for NMRA-511 in Alzheimer’s disease agitation by the end of 2026. The company also announced a leadership transition effective August 14, 2026, with Joshua Pinto, Ph.D. becoming president and chief executive officer and joining the Board, while co-founder Paul L. Berns becomes Executive Chair.
Neumora Therapeutics, Inc. reported favorable pre-clinical toxicology results for NMRA-215, a highly brain-penetrant, oral NLRP3 inhibitor being developed for obesity and cardiometabolic disorders. In a repeat 13-week rat toxicology study of 162 animals, no unexpected in-life adverse findings were observed.
The repeat study followed an earlier 13-week rat study in which 5 of 142 animals showed unexpected adverse findings; after a for-cause audit and review of all rat and dog toxicology data, the company continues to believe those findings were not related to NMRA-215. Based on the toxicology package and pre-clinical efficacy data in a diet-induced obesity mouse model, Neumora plans to submit an IND for NMRA-215 in the fourth quarter of 2026 and to initiate a Phase 1 study by the end of 2026.
Neumora Therapeutics reported that its Phase 3 KOASTAL‑2 and KOASTAL‑3 trials of navacaprant in major depressive disorder failed to achieve statistical significance on primary or key secondary endpoints, and the company is discontinuing development of navacaprant. KOASTAL‑2 and KOASTAL‑3 enrolled 430 and 422 adult patients, respectively, and showed similar or numerically worse depression score changes versus placebo.
Neumora is implementing a workforce reduction of approximately 35%, expecting about $10 million in annualized cost savings, partially offset by about $2 million in one‑time restructuring costs in the second quarter of 2026. Following these changes, the company expects its current cash and cash equivalents to provide runway into the third quarter of 2027 while it focuses on NMRA‑511 in Alzheimer’s disease agitation, NMRA‑898 in schizophrenia and NMRA‑215 in cardiometabolic disease. Neumora also entered a Third Amendment to its Loan and Security Agreement, extending the interest‑only period and revising a minimum liquidity covenant tied to milestones and market capitalization.
Neumora Therapeutics, Inc. reported results from its annual meeting of stockholders. Three Class III directors — Paul L. Berns, Matthew Fust and David Piacquad — were elected to serve until the 2029 annual meeting. Stockholders also ratified Ernst & Young LLP as independent auditor for the fiscal year ending December 31, 2026.
Stockholders approved, on an advisory basis, the compensation of the company’s named executive officers and supported holding future advisory votes on executive pay every year. The voting was based on 182,688,076 common shares outstanding and entitled to vote as of the April 7, 2026 record date.
Neumora Therapeutics reported first quarter 2026 results, highlighting lower operating expenses and an extended cash runway as it advances its neuroscience pipeline. Research and development expenses fell to $38.6 million from $52.2 million a year earlier, while general and administrative expenses decreased to $14.3 million from $18.8 million.
Net loss narrowed to $53.5 million, compared with $68.0 million in the first quarter of 2025, with loss per share improving to $0.30 from $0.42. Neumora ended March 31, 2026 with $147.1 million in cash and cash equivalents, which it expects will fund its operating plan into the third quarter of 2027 while it progresses navacaprant, NMRA‑511, NMRA‑898 and NMRA‑215 through key clinical milestones.
Neumora Therapeutics reported fourth-quarter and full-year 2025 results alongside major pipeline updates. The company recorded a Q4 2025 net loss of $59.4 million and a full-year 2025 net loss of $236.9 million, reflecting continued investment in R&D-led growth.
Research and development expenses were $176.1 million in 2025, down from $200.9 million in 2024, while general and administrative expenses eased to $60.1 million. Neumora ended 2025 with $182.5 million in cash, cash equivalents and marketable securities, which it expects will fund operations into the third quarter of 2027.
Pipeline news included new Phase 1b data for NMRA-511 in Alzheimer’s disease agitation showing effect sizes up to 0.51 on agitation measures, with a Phase 2 study planned for Q1 2027. The KOASTAL-2 and -3 navacaprant studies are fully enrolled with a joint topline readout expected in Q2 2026. Neumora named NMRA-898 its lead M4 program for schizophrenia based on promising Phase 1 data, and highlighted positive obesity data for NMRA-215 while repeating a 13-week rat toxicology study, now targeting clinical entry in Q1 2027.
Neumora Therapeutics furnished a corporate presentation for use at the Guggenheim Emerging Outlook: Biotech Summit, highlighting Phase 1b data for NMRA-511 in agitation associated with Alzheimer’s disease. The randomized, double-blind study enrolled 40 patients on NMRA-511 and 40 on placebo over eight weeks, plus a small healthy-elderly cohort.
In a pre-specified elevated anxiety subgroup, NMRA-511 showed Cohen’s d effect sizes of 0.51–0.64 on the CMAI agitation scale, up to 0.78 on CGI-S agitation, and 0.42–0.46 on the NPI agitation/aggression domain, with nominal p-values down to <0.05. Treatment-emergent adverse events were generally mild to moderate, discontinuations due to side effects were 2.5%, and one serious adverse event resolved fully. The company notes potential for higher dosing and future studies that enrich for patients with elevated anxiety.
Neumora Therapeutics, Inc. furnished a new corporate presentation that it plans to use in meetings with investors and analysts at the 44th Annual J.P. Morgan Healthcare Conference. The presentation, dated January 2026, is provided as Exhibit 99.1 to this report and is incorporated into the report by reference.
The company notes that the presentation and related information are being furnished, not filed, which means they are not subject to certain liability provisions under federal securities laws and will not automatically be incorporated into other SEC documents.
Neumora Therapeutics, Inc. reported that its lender K2 HealthVentures exercised a conversion right under an existing Loan and Security Agreement. K2 HealthVentures converted $2.5 million of term loan principal into common stock at a price of $0.8774 per share, as allowed under the agreement that permits conversion of up to $12.5 million of principal. On November 20, 2025, Neumora issued 2,849,327 shares of common stock to K2 HealthVentures Equity Trust LLC in connection with this conversion. The shares were issued as a private offering relying on the registration exemption in Section 4(a)(2) of the Securities Act of 1933.
Neumora Therapeutics, Inc. furnished an 8-K stating it announced financial results for the second quarter ended September 30, 2025. The full details are provided in a press release attached as Exhibit 99.1.
The company notes that the information under Item 2.02, including Exhibit 99.1, is being furnished and is not deemed filed under the Exchange Act. The report was signed by Chief Financial Officer Michael Milligan on November 6, 2025.
Neumora Therapeutics (NMRA) reported an operational update under Item 8.01. On October 27, 2025, the company announced the initiation of a Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study of NMRA-898. The related press release was furnished as Exhibit 99.1.
This is an early clinical development milestone disclosed via an 8-K and does not include financial results or guidance.
Neumora Therapeutics (NMRA) filed an 8‑K announcing positive preclinical data for NMRA‑215. The company reported class‑leading weight loss in diet‑induced obesity mouse studies: up to 19% as a monotherapy with semaglutide‑like induction, and 26% when combined with high doses of semaglutide. The announcement was made on October 27, 2025.
A press release with additional details was furnished as Exhibit 99.1 and incorporated by reference.